Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Commercial identity or variant awaiting clarification.
Mechanism
“Mechano growth factor” may mean an IGF-1 transcript, its E region or a synthetic peptide; these are not equivalent identities.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance · Recovery and connective tissue
Promoted for muscle/tendon repair; retain separately from PEG-MGF and IGF-1 LR3.
Human evidence
The selected work studied mechanically injured human ligament cells and a rabbit injury model. Human cells do not mean treated human patients.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The selected work studied mechanically injured human ligament cells and a rabbit injury model. Human cells do not mean treated human patients.
The selected work studied mechanically injured human ligament cells and a rabbit injury model. Human cells do not mean treated human patients.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No clinical regimen or commercial-modification safety was established; GH/IGF-1 combination safety is also not demonstrated.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID35457148 · Cells and animal model
Human ACL cells/injured rabbits.
In vitro/animal model.
Cell mobility/experimental ligament repair.
No treated patients or commercial PEG-MGF validation.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
MGF · 102 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT03851614 · Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsRegistry status: Active, not recruitingLast update posted: October 5, 2026Query verification: October 16, 2026
NCT07037420 · ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyRegistry status: TerminatedLast update posted: August 7, 2026Query verification: October 16, 2026
NCT03253263 · A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsRegistry status: Active, not recruitingLast update posted: August 3, 2026Query verification: October 16, 2026
Source issues and references
600 mcg/day for five days would imply 3 mg/week versus the written 2-mg limit; PEG-MGF handbooks also conflict. · manual01 · Page 98
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID35457148
Sha Y, Zhang B, Chen L, Hong H, Chi Q.
October 16, 2026
- SEARCH-PUBMED-mgf
PubMed/MED targeted search: TITLE_ABS:"mechano growth factor" AND TITLE_ABS:human
October 16, 2026
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026